Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: A correlation with resistance against doxorubicin

Journal of Surgical Oncology

Volumn 61, Issue 3, 1996, Pages 223-229

  Murase, Masaharu ^a   Kodera, Yasuhiro ^a,b   Kondo, Ken ^a   Sekiguchi, Hiroyuki ^a   Fujiwara, Michitaka ^a   Kasai, Yasushi ^a,b   Akiyama, Seiji ^a   Ito, Katsuki ^a   Takagi, Hiroshi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

doxorubicin; multidrug resistance; pirarubicin; polymerase chain reaction

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; MEMBRANE PROTEIN; MESSENGER RNA; PIRARUBICIN;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ONCOGENES; P-GLYCOPROTEIN; PHENOTYPE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0029932449     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199603)61:3<223::AID-JSO12>3.0.CO;2-8     Document Type: Article

References (31)

1. Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285-1288, 1983.
2. Satta T, Isobe K, Yamauchi M, et al.: Establishment of drug resistance in human gastric and colon carcinoma xenograft lines. Jpn J Cancer Res 82:593-598, 1991.
3. Kramer R, Weber TK, Morse B, et al.: Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 67:959-968, 1993.
4. Lai SL, Goldstein LJ, Gottesman MM, et al.: MDR1 gene expression in lung cancer. J Natl Cancer Inst 81:1144-1150, 1989.
5. Yamauchi M, Kumazawa H, Satta T, et al.: Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining. Eur J Cancer 28A:1422-1427, 1992.
6. Mirski SEL, Gerlach JH, Cole SPC: Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin. Cancer Res 47:2594-2598, 1987.
7. Nielsen D, Skovsgaard T: P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochem Biophys Acta 1139:169-183, 1992.
8. Cole SPC, Bhardwaj G, Gerlach JH et al.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654, 1992.
9. Krishnamachary N, Center MS: The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 53:3658-3661, 1993.
10. Barrand MA, Heppell-Parton AC, Wright KA, et al.: A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 86:110-117, 1994.
11. Schneider E, Horton JK, Yang C-H, et al.: Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54:152-158, 1994.
12. Cole SPC, Sparks KE, Fraser K, et al.: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910, 1994.
13. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, et al.: Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1:81-93, 1995.
14. Umezawa H, Takahashi Y, Kinoshita M, et al.: Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot 32:1082-1084, 1979.
15. Akiyama S, Amo H, Watanabe T, et al.: Characteristics of three human gastric cancer cell lines, NUGC2, NUGC3, NUGC4. Jpn J Surg 18:438-446, 1988.
16. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987.
17. Wang AM, Doyle VM, Mark D: Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci (Wash) 86:9717-9721, 1989.
18. Noonan KE, Beck C, Holzmayer TA, et al.: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci (Wash) 87:7160-7164, 1990.
19. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T: Molecular structure of the human cytoplasmic β-actin gene: Interspecies homology of sequences in the introns. Proc Natl Acad Sci (Wash) 82:6133-6137, 1985.
20. Kwok S, Higuchi R: Avoiding false positive with PCR. Nature 339:237-238, 1989.
21. Satta T, Isobe K, Yamauchi M, et al.: Expression of MDR1 and glutathione S transferase-π genes and chemosensitivities in human gastrointestinal cancer. Cancer 69:943-946, 1992.
22. Yamauchi M, Satta T, Ito A, et al.: A feasibility study of the SDI test for the evaluation of gastrointestinal cancer sensitivity to anticancer drugs. J Surg Oncol 47:253-260, 1991.
23. Kodera Y, Isobe K, Yamauchi M, et al.: Expression of glutathione-S-transferases α and π in gastric cancer: A correlation with cisplatin resistance. Cancer Chemother Pharmacol 34:203-208, 1994.
24. Kodera Y, Akiyama S, Isobe K, et al.: Expression of π-glutathione S-transferase gene (GSTP1) in gastric cancer: Lack of correlation with resistance against cis-diamminedichloroplatinum (II). Eur J Cancer 30A:2158-2162, 1994.
25. Moertel CG, Rubin J, O'Connel, MJ, et al.: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4:1053-1057, 1986.
26. Preusser P, Wilke H, Achterrath W, et al.: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310-1317, 1989.
27. Keith WN, Stallard S, Brown R: Expression of mdr1 and gst-π in human breast tumours: comparison to in vitro chemosenstivity. Br J Cancer 61:712-716, 1990.
28. Grant CE, Valdimarsson G, Hipfner D, et al.: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361, 1994.
29. Brock I, Hipfner D, Nielsen BS, et al.: Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 55:459-162, 1995.
30. Almquist KC, Loe DW, Hipfner DR, et al.: Characterization of the Mr 190000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 55:102-110, 1995.
31. Maehara Y, Sakaguchi Y, Kusumoto T, et al.: 4′-0-tetrahydropyranyl-adriamycin has greater antineoplastic activity than adriamycin in various human tumours in vitro. Anticancer Res 9:387-390, 1989.